BIOMAT Database Logo BIOMAT Database Logo

29-week doxazosin treatment in patients with symptomatic benign prostatic hyperplasia. A double-blind placebo-controlled study. 1994

J Bendix Holme, and M M Christensen, and P C Rasmussen, and F Jacobsen, and J Nielsen, and J P Nørgaard, and S Olesen, and I Noer, and H Wolf, and S Elkjaer Husted
Department of Surgery K, Skejby Hospital, University Hospital of Aarhus, Denmark.

In a placebo-controlled study, the safety and efficacy of the selective alpha 1-adrenoceptor-blocking agent doxazosin 4 mg once daily in the symptomatic treatment of benign prostatic hyperplasia (BPH) were evaluated. One hundred patients were primarily included in a 9-weeks study, and after this 75 patients accepted to continue in the present 20 weeks extension. Of the patients in the doxazosin-group (DG) 61% reported overall improvement against 53% in the placebo-group (PG)--(p = 0.56). In the DG, 49% of obstructive symptoms were improved compared to 27% in the PG (p < 0.01), and a reduction of 60% of irritative symptoms was found in the DG against 36% in the PG (p < 0.01). Daytime frequency was reduced by median 1.5 in the DG and remained unchanged in the PG (p < 0.01). Nocturia was reduced by median 1 and 0.5 respectively (p = 0.06). Maximum urinary flow rate (MFR) was improved by median 1.5 ml/s in the DG, while it deteriorated by median 0.5 ml/s in the PG (p < 0.05), Considering postvoid residual urine volume, cystometry variables (first sensation and bladder capacity), changes in sexual function and adverse events there was no difference between the two groups. In conclusion, doxazosin 4 mg once daily in long-term treatment of patients with BPH reduces both obstructive and irritative symptoms, daytime voiding frequency and although only slightly, significantly augments MFR without interference with sexual function and without other serious adverse effects.

UI MeSH Term Description Entries
D008134 Long-Term Care Care over an extended period, usually for a chronic condition or disability, requiring periodic, intermittent, or continuous care. Care, Long-Term,Long Term Care
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011470 Prostatic Hyperplasia Increase in constituent cells in the PROSTATE, leading to enlargement of the organ (hypertrophy) and adverse impact on the lower urinary tract function. This can be caused by increased rate of cell proliferation, reduced rate of cell death, or both. Adenoma, Prostatic,Benign Prostatic Hyperplasia,Prostatic Adenoma,Prostatic Hyperplasia, Benign,Prostatic Hypertrophy,Prostatic Hypertrophy, Benign,Adenomas, Prostatic,Benign Prostatic Hyperplasias,Benign Prostatic Hypertrophy,Hyperplasia, Benign Prostatic,Hyperplasia, Prostatic,Hyperplasias, Benign Prostatic,Hypertrophies, Prostatic,Hypertrophy, Benign Prostatic,Hypertrophy, Prostatic,Prostatic Adenomas,Prostatic Hyperplasias, Benign,Prostatic Hypertrophies
D001748 Urinary Bladder Neck Obstruction Blocked urine flow through the bladder neck, the narrow internal urethral opening at the base of the URINARY BLADDER. Narrowing or strictures of the URETHRA can be congenital or acquired. It is often observed in males with enlarged PROSTATE glands. Bladder Neck Obstruction,Bladder Outlet Obstruction
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

J Bendix Holme, and M M Christensen, and P C Rasmussen, and F Jacobsen, and J Nielsen, and J P Nørgaard, and S Olesen, and I Noer, and H Wolf, and S Elkjaer Husted
Reproducibility of uroflow measurement: experience during a double-blind, placebo-controlled study of doxazosin in benign prostatic hyperplasia.
May 1996, Urology,
J Bendix Holme, and M M Christensen, and P C Rasmussen, and F Jacobsen, and J Nielsen, and J P Nørgaard, and S Olesen, and I Noer, and H Wolf, and S Elkjaer Husted
A 12-week placebo-controlled double-blind study of prazosin in the treatment of prostatic obstruction due to benign prostatic hyperplasia.
September 1992, British journal of urology,
J Bendix Holme, and M M Christensen, and P C Rasmussen, and F Jacobsen, and J Nielsen, and J P Nørgaard, and S Olesen, and I Noer, and H Wolf, and S Elkjaer Husted
A randomized, double-blind crossover study of tamsulosin and controlled-release doxazosin in patients with benign prostatic hyperplasia.
January 2003, BJU international,
J Bendix Holme, and M M Christensen, and P C Rasmussen, and F Jacobsen, and J Nielsen, and J P Nørgaard, and S Olesen, and I Noer, and H Wolf, and S Elkjaer Husted
Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: a double-blind, placebo-controlled, dose-response multicenter study.
July 1995, The Journal of urology,
J Bendix Holme, and M M Christensen, and P C Rasmussen, and F Jacobsen, and J Nielsen, and J P Nørgaard, and S Olesen, and I Noer, and H Wolf, and S Elkjaer Husted
A double-blind placebo-controlled study evaluating the onset of action of doxazosin gastrointestinal therapeutic system in the treatment of benign prostatic hyperplasia.
September 2005, European urology,
J Bendix Holme, and M M Christensen, and P C Rasmussen, and F Jacobsen, and J Nielsen, and J P Nørgaard, and S Olesen, and I Noer, and H Wolf, and S Elkjaer Husted
Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies.
September 1996, Urology,
J Bendix Holme, and M M Christensen, and P C Rasmussen, and F Jacobsen, and J Nielsen, and J P Nørgaard, and S Olesen, and I Noer, and H Wolf, and S Elkjaer Husted
Doxazosin for the symptomatic treatment of benign prostatic hyperplasia.
August 2003, Current urology reports,
J Bendix Holme, and M M Christensen, and P C Rasmussen, and F Jacobsen, and J Nielsen, and J P Nørgaard, and S Olesen, and I Noer, and H Wolf, and S Elkjaer Husted
Effect of doxazosin on the symptoms of benign prostatic hyperplasia: results from three double-blind placebo-controlled studies.
January 1997, International journal of clinical practice,
J Bendix Holme, and M M Christensen, and P C Rasmussen, and F Jacobsen, and J Nielsen, and J P Nørgaard, and S Olesen, and I Noer, and H Wolf, and S Elkjaer Husted
Urtica dioica for treatment of benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled, crossover study.
January 2005, Journal of herbal pharmacotherapy,
J Bendix Holme, and M M Christensen, and P C Rasmussen, and F Jacobsen, and J Nielsen, and J P Nørgaard, and S Olesen, and I Noer, and H Wolf, and S Elkjaer Husted
[Efficacy of a combined Sabal-urtica preparation in the symptomatic treatment of benign prostatic hyperplasia. Results of a placebo-controlled double-blind study].
October 2005, MMW Fortschritte der Medizin,
Copied contents to your clipboard!